Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by multifocal fibrosis of both intra- and extra-hepatic bile ducts. It is associated with ulcerative colitis in 70–80% of cases. The disease course is variable but often progresses to end-stage liver disease leading to liver transplantation. Currently, there is no approved medical treatment for PSC. Management focuses on symptomatic relief and treatment of complications.

The global primary sclerosing cholangitis market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The primary driver impacting the primary sclerosing cholangitis market growth is the rising prevalence of the disease. According to data by the National Organization of Rare Disorders, PSC affects 1 in 10,000 people in the United States and Europe. It commonly occurs in individuals between 30-50 years of age. Moreover, the disease prevalence shows a continuous rising trend owing to unknown etiology. There is no known cause of PSC however genetics and immune system abnormalities are considered risk factors. Currently, autoimmune mechanism is believed to be responsible for destruction and fibrosis of bile ducts in PSC patients. The only available treatment options provide symptomatic relief and aim to delays disease progression. Hence, there is a huge unmet need for effective and novel therapies for PSC treatment. This provides lucrative opportunities for players in the primary sclerosing cholangitis market for development of targeted therapies and treatment options.

SWOT Analysis

Strength: Primary Sclerosing Cholangitis Market has witnessed significant research and development activities over the past few years. The increasing prevalence of Primary Sclerosing Cholangitis and growing awareness regarding its treatment options are expected to drive the market growth. Furthermore, the launch of new drugs with novel mechanisms of action is also supporting the growth of the Primary Sclerosing Cholangitis Market.

Weakness: However, high treatment costs associated with Primary Sclerosing Cholangitis medications pose a major challenge for market growth. In addition, lack of approved drug therapies and limitations of current treatment modalities further limit the Primary Sclerosing Cholangitis Market expansion.

Opportunity: The Primary Sclerosing Cholangitis Market provides opportunities for key players to develop new drugs with improved efficacy and safety. Moreover, ongoing clinical trials evaluating new drug candidates offer promising growth prospects. Untapped emerging markets also present remunerative opportunities for market players.

Threats: Nevertheless, strict regulatory norms for drug approval and long drug development timelines hamper the progress of the Primary Sclerosing Cholangitis Market. Limited understanding of disease etiology and pathogenesis also poses a major threat.

Key Takeaways

The global Primary Sclerosing Cholangitis Market Growth is expected to witness high growth. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.

Regional analysis related content comprises Regional analysis related content The North America region currently dominates the global Primary Sclerosing Cholangitis market owing to growing patient population, rising disease awareness, and strong presence of key market players in the region. Moreover, continual government support for research activities is also boosting the market growth. The Asia Pacific market is projected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure and rising healthcare expenditure in emerging countries.

Key players related content comprises Key players related content Key players operating in the Primary Sclerosing Cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

For more insights, read- https://dailynewsmotion.weebly.com/report-blog/primary-sclerosing-cholangitis-market-is-estimated-to-witness-high-growth-owing-to-rising-disease-prevalence